Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Valuation & Earnings
This table compares Fate Therapeutics and Syndax Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $6.65 million | 42.34 | -$136.32 million | ($1.05) | -2.24 |
| Syndax Pharmaceuticals | $172.35 million | 9.36 | -$285.42 million | ($2.51) | -7.25 |
Profitability
This table compares Fate Therapeutics and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -65.08% | -41.73% |
| Syndax Pharmaceuticals | -87.52% | -372.94% | -39.11% |
Analyst Ratings
This is a summary of current ratings for Fate Therapeutics and Syndax Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 3 | 4 | 0 | 2.38 |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
Fate Therapeutics presently has a consensus target price of $5.90, suggesting a potential upside of 151.06%. Syndax Pharmaceuticals has a consensus target price of $42.30, suggesting a potential upside of 132.42%. Given Fate Therapeutics’ higher possible upside, equities research analysts plainly believe Fate Therapeutics is more favorable than Syndax Pharmaceuticals.
Risk & Volatility
Fate Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
Institutional and Insider Ownership
97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Fate Therapeutics beats Syndax Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
